Stifel Financial’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $26.4M | Buy |
139,514
+16,765
| +14% | +$2.93M | 0.02% | 530 |
|
|
2025
Q4 | $20.9M | Sell |
122,749
-3,171
| -3% | -$486K | 0.02% | 622 |
|
|
2025
Q3 | $16.6M | Sell |
125,920
-28,398
| -18% | -$3.41M | 0.02% | 700 |
|
|
2025
Q2 | $16.4M | Sell |
154,318
-27,265
| -15% | -$2.96M | 0.02% | 672 |
|
|
2025
Q1 | $22.5M | Buy |
181,583
+3,255
| +2% | +$425K | 0.02% | 525 |
|
|
2024
Q4 | $22M | Buy |
178,328
+36,253
| +26% | +$4.27M | 0.02% | 540 |
|
|
2024
Q3 | $15.8M | Buy |
142,075
+20,675
| +17% | +$2.27M | 0.02% | 685 |
|
|
2024
Q2 | $13M | Buy |
121,400
+11,938
| +11% | +$1.31M | 0.01% | 720 |
|
|
2024
Q1 | $13.2M | Buy |
109,462
+57,555
| +111% | +$7.05M | 0.02% | 705 |
|
|
2023
Q4 | $6.38M | Sell |
51,907
-15,182
| -23% | -$1.89M | 0.01% | 977 |
|
|
2023
Q3 | $8.68M | Buy |
67,089
+3,440
| +5% | +$458K | 0.01% | 776 |
|
|
2023
Q2 | $7.89M | Buy |
63,649
+11,841
| +23% | +$1.59M | 0.01% | 816 |
|
|
2023
Q1 | $7.58M | Buy |
51,808
+2,847
| +6% | +$421K | 0.01% | 803 |
|
|
2022
Q4 | $7.8M | Buy |
48,961
+2,016
| +4% | +$295K | 0.01% | 765 |
|
|
2022
Q3 | $6.26M | Buy |
46,945
+12,476
| +36% | +$1.9M | 0.01% | 836 |
|
|
2022
Q2 | $5.38M | Buy |
34,469
+5,529
| +19% | +$851K | 0.01% | 939 |
|
|
2022
Q1 | $4.5M | Buy |
28,940
+6,064
| +27% | +$880K | 0.01% | 1110 |
|
|
2021
Q4 | $2.92M | Sell |
22,876
-6,911
| -23% | -$908K | ﹤0.01% | 1374 |
|
|
2021
Q3 | $3.88M | Buy |
29,787
+3,302
| +12% | +$499K | 0.01% | 1153 |
|
|
2021
Q2 | $4.71M | Buy |
26,485
+7,132
| +37% | +$1.24M | 0.01% | 1055 |
|
|
2021
Q1 | $3.18M | Buy |
19,353
+6,401
| +49% | +$1.05M | 0.01% | 1226 |
|
|
2020
Q4 | $2.14M | Sell |
12,952
-438
| -3% | -$65.2K | ﹤0.01% | 1346 |
|
|
2020
Q3 | $1.91M | Buy |
13,390
+2,623
| +24% | +$325K | ﹤0.01% | 1237 |
|
|
2020
Q2 | $1.19M | Buy |
10,767
+2,211
| +26% | +$245K | ﹤0.01% | 1438 |
|
|
2020
Q1 | $847K | Sell |
8,556
-27,317
| -76% | -$3.53M | ﹤0.01% | 1536 |
|
|
2019
Q4 | $5.33M | Sell |
35,873
-2,686
| -7% | -$366K | 0.01% | 860 |
|
|
2019
Q3 | $4.93M | Buy |
38,559
+155
| +0.4% | +$20.8K | 0.01% | 838 |
|
|
2019
Q2 | $5.48M | Buy |
38,404
+1,506
| +4% | +$202K | 0.01% | 827 |
|
|
2019
Q1 | $5.27M | Buy |
36,898
+11,226
| +44% | +$1.46M | 0.01% | 797 |
|
|
2018
Q4 | $3.16M | Sell |
25,672
-1,606
| -6% | -$238K | 0.01% | 956 |
|
|
2018
Q3 | $4.6M | Buy |
27,278
+3,011
| +12% | +$518K | 0.01% | 879 |
|
|
2018
Q2 | $4.18M | Buy |
24,267
+3,406
| +16% | +$557K | 0.01% | 892 |
|
|
2018
Q1 | $3.16M | Buy |
20,861
+2,518
| +14% | +$369K | 0.01% | 967 |
|
|
2017
Q4 | $2.45M | Sell |
18,343
-8,413
| -31% | -$1.17M | 0.01% | 1063 |
|
|
2017
Q3 | $3.91M | Sell |
26,756
-4,502
| -14% | -$681K | 0.01% | 830 |
|
|
2017
Q2 | $4.87M | Buy |
31,258
+597
| +2% | +$91.3K | 0.02% | 721 |
|
|
2017
Q1 | $4.45M | Buy |
30,661
+2,556
| +9% | +$333K | 0.02% | 746 |
|
|
2016
Q4 | $3.06M | Sell |
28,105
-5,754
| -17% | -$641K | 0.01% | 858 |
|
|
2016
Q3 | $4.11M | Sell |
33,859
-3,876
| -10% | -$522K | 0.02% | 709 |
|
|
2016
Q2 | $5.19M | Buy |
37,735
+762
| +2% | +$112K | 0.02% | 590 |
|
|
2016
Q1 | $4.83M | Sell |
36,973
-2,031
| -5% | -$253K | 0.03% | 556 |
|
|
2015
Q4 | $5.48M | Sell |
39,004
-3,725
| -9% | -$516K | 0.03% | 521 |
|
|
2015
Q3 | $5.67M | Buy |
42,729
+9,300
| +28% | +$1.6M | 0.03% | 473 |
|
|
2015
Q2 | $5.88M | Buy |
33,429
+1,640
| +5% | +$295K | 0.03% | 504 |
|
|
2015
Q1 | $5.49M | Buy |
31,789
+9,484
| +43% | +$1.63M | 0.03% | 584 |
|
|
2014
Q4 | $3.65M | Buy |
22,305
+3,337
| +18% | +$554K | 0.02% | 676 |
|
|
2014
Q3 | $3.04M | Buy |
18,968
+7,301
| +63% | +$1.12M | 0.03% | 633 |
|
|
2014
Q2 | $1.72M | Buy |
11,667
+4,484
| +62% | +$622K | 0.02% | 836 |
|
|
2014
Q1 | $996K | Buy |
+7,183
| New | +$1.08M | 0.01% | 1076 |
|
Other funds holding JAZZ
VPM
VCM
EC
Stifel Financial's JAZZ Position: Q1 2026 in Review
Stifel Financial increased its Jazz Pharmaceuticals (JAZZ) stake by 14% in Q1 2026, buying an estimated $2.93M and bringing the position to 139,514 shares worth $26.4M. The position accounts for 0.02% of the portfolio, ranked #530.
Stifel Financial first reported a position in JAZZ in Q1 2014 and has held it in 49 quarters since. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.
- Stifel Financial held 139,514 shares of Jazz Pharmaceuticals worth $26.4M as of Q1 2026.
- Stifel Financial bought 16,765 Jazz Pharmaceuticals shares in Q1 2026, an estimated $2.93M.
- Jazz Pharmaceuticals made up 0.02% of Stifel Financial's portfolio in Q1 2026, its #530 holding.
- Stifel Financial first reported a position in Jazz Pharmaceuticals in Q1 2014 and has held it in 49 quarters since.
- 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.
Based on Stifel Financial's 13F filing for Q1 2026, filed 12 May 2026.